MAY 26 2004

TECH CENTER 1609/2499. Docket: UCONAP/141/US

In re patent application of first named inventor: Alexandros Makriyannis et al

Application No.:

09/328,742

Examiner:

A. N. Pryor

Filing Date:

June 6, 1999

Group Art Unit:

1616

For:

Inhibitors Of The Anandamide Transporter As Analgesic Agents

TRANSMITTAL LETTER

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Sir, enclosed herewith is (are):

- Information Disclosure Statement
- check for \$180.00
- return postcard

It is hereby petitioned that any required extension of time be granted for filing the enclosed papers. An extension of 0 month(s) having a fee of \$0 appears required.

If checked, claims are being amended. subtotal claim No. of claims remaining Highest no. of claims no. fee after amendment previously paid for extra \$ \$0.00 Total \$0.00 Independent

Total claim fees

0.00

 ⊠ If checked, a check in the amount of \$180.00 is attached. Please credit any overpayment
 to Deposit Account 16-2563 of Alix, Yale & Ristas, LLP.

The Commissioner is hereby requested and authorized to charge Deposit Account 16-2563 of Alix, Yale & Ristas, LLP for any required extension fee and for any other fee, not enclosed herewith, due for any reason during the pendency of this application or in connection with the accompanying document, including (a) any filing fees under 37 CFR 1.16 for the presentation of extra claims and (b) any patent application processing fees under 37 CFR 1.17. A duplicate copy of this letter is enclosed.

Alix, Yale & Ristas, LLP 750 Main Street- Suite 1400 Hartford, CT 06103-2721

(860) 527-9211

James E. Plotrowski Registration No. 43,860

Attorney for Applicant

The above signatory certifies that this correspondence is being deposited on the date given above with the United States Postal Service as First Class Mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450".

JEP/db/enclosures

G:\AYR saved docs\Filing Docs\Uconap\uconap141us\uconap141us 5-04 ids transmittal.doc



M Attorney Docket: UCONAP/141/US

IN THE UNITED STATES PATENT, AND TRADEMARK OFFICE

In re patent application of: Alexandros MAKRIYANNIS et al

Application No.:

09/328,742

Examiner:

A. N. Pryor

Filing Date:

June 6, 1999

Group Art Unit:

1616

For:

INHIBITORS OF THE ANANDAMIDE

TRANSPORTER AS ANALGESIC AGENTS

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Sir:

Information Disclosure Statement

Applicant submits herewith patents, publications or other information of which they are aware and which they believe may be material to the examination of the above-identified application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(b) exists.

For US national applications filed after June 30, 2003 and International applications that have entered the national stage after June 30, 2003 a copy of a cited US patent or cited US patent publication is NOT required. See OG Notices: 5 August 2003. Accordingly, no copies of a cited US patent or cited US patent publication are enclosed.

AYR 11/03

Attorney Docket: UCONAP/141/US

A copy of each item other than a US patent or a US patent publication listed on the attached INFORMATION DISCLOSURE CITATION IN AN APPLICATION is supplied herewith.

For US national applications filed before June 30, 2003 and International applications that have entered the national stage before June 30, 2003 a copy of each of the items listed on the attached INFORMATION DISCLOSURE CITATION IN AN APPLICATION is supplied herewith.

Citations preceded with *** indicate references for which Applicant has no copy to submit. If a sample of any of these references can be procured the same will be filed in a subsequent IDS.

By:

Respectfully submitted,

lames E. Piotrowski Registration No. 43,860

Alix, Yale & Ristas, LLP

Attorney for Applicants

Alexandros Makriyannis et al.

750 Main Street- Suite 1400

Hartford, CT 06103-2721

(860) 527-9211

JEP/db/enclosures

G:\AYR saved docs\Filing Docs\Uconap\uconap141us\uconap141us 5-04 ids.doc

PE VC TRIBUTE

WHY 26 SULTA

MFORMATION DISCLOSURE CITATION IN AN APPLICATION

May 18, 2004

Application No. 09/328,742

Alexandros Makriyannis et al

Title

Inhibitors Of The Anandamide Transporter As Analgesic Agents

Filing Date
June 6, 1999

Group Art Unit 1616 Docket No. UCONAP/141/US

UNITED STATES PATENT DOCUMENTS

					Class	
Examiner Initial	Document No.	Date		Name		
	09/600786		to Makriyannis et al (US National phase of Int'l App. No. PCT/US99/28136, published as WO 00/32200)		ie	
	09/701989		to Makriyannis et al (US National phase of Int'l App. No. PCT/US99/12900, published as WO 00/64389)		ie	
··	3465024		to Brown	to Brownstein et al		
	3577458		to Brownstein et al		-	
-	4812457		to Narumiya			
	5576436		to McCabe et al.			
	5618955		to Mechoulam et al			
	5688825		to Makriyannis et al			
	5804601		to Kato et al			
	5925628		to Lee et al			
	6391909		to Makriyannis et al			
	6579900		to Makriyannis et al			
		FORFIG	N DATENT	DOCUMENTS		
		FOREIG		DOCUMENTS		
Examiner Initial		Date	Country	Name	Translation	
Examiner		OCUMEN	TS (Including A	author, Title, Date, Pertinent Pages, Etc.)		
Initial	itial					
	Barnett-Norris anandamide,	et al; "exp "; J. Me	oloration of ed. Chem.;	biologically relevant conforma vol. 41; 4861-4872; 1998	ations of	



INFORMATION DISCLOSURE
OF TATION IN AN
APPLICATION

Application No. O9/328,742 Inventor Alexandros Makriyannis et al

Inhibitors Of Th Anandamide Transp rt r As Analg sic Agents

Filing Date Group Art Unit Docket No.

June 6, 1999 1616 UCONAP/141/US

Berglund et al; "Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: . . ."; Prostanglandins, leukotrienes ands essential fatty acids; 59(2); 111-118; (1998). (abstract only)

*** BioWorld Today, Volume 8(162), August 21, 1997

Cherest M., Luscindi X.; "The action of acetyl chloride and of acetic anhydride on the lithium nitronate salt of 2-phenylnitroethane . . ."; Tetrahedron; 42(14); 3825-3840; 1986; in French with English abstract Cherest M., Lusinchi X.; "A novel electrophilic N-amidation via electron deficient complexes: action of ferric chloiride on N-acetyloxyamides"; Tetrahedron Letters; 30(6); 715-718; 1989

*** Compton D.R. et al; J. Pharmacol. Exp. Ther.; 260; 201-209; 1992

*** D'Amour F.E., Smith D.L.; J. Pharmacol. Exp. Ther.; 72; 74-79; 1941

Demuynck L. et al; "Rearrangement of Indolo[2,3-a]quinolizidines to derivatives with E-azaaspidospermane skeleton"; Tetrahedron Letters; 30(6) 710-722; 1989; in French with English abstract

Deutsch D.G. et al; "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to cannabinoid receptor"; Biochem. Biophys. Res. Commun. 231(1); 217-221; 1997; CODEN: BBRCA9; ISSN:0006-291X; XP002040933

Deutsch D.G., Chin S.A.; "Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist"; Biochemical Pharmacology; 46(5); 791-796; 1993

Fride & Mechoulam; "Pharmacological activity of the cannabinoid receptor agonist; . . . "; European Journal of Pharmacology, vol. 231; 313-314; 1993

Hillard C. J., Edgemond, W. S., Jarrahian W., Campbell, W. B; "Accumulation of N-Arachidonoylethanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion"; Journal of Neurochemistry; 69; 631-638 (1997)

Horrevoets A.J.G et al; "Inactivation of escherichia coli outer membrane phospholipase A by the affinity label hexadecanesulfonyl fluoride"; Eur. J. Biochem.; 198; 247-253; 1991

Kawase M. et al; "Electrophilic aromatic substitution with N-methoxy-N-acylnitrenium ions generated from N-chloro-N-methoxyamides: synthesis of nitrogen heterocyclic compounds bearing a N-methoxyamide group"; J. Org. Chem.; 54; 3394-3403; 1989

MAY 26 2004

ORMATION DISCLOSURE	Application No. 09/328,742	Inventor	Makriyannis et al			
APPLICATION	Title Inhibit rs Of The Anandamid Transp rter As Analg sic Agents					
	Filing Date June 6, 1999	Group Art Unit 1616	Docket No. UCONAP/141/US			
Koutek B. et al; "Inhik Chem.; 269(37); 229 XP002040931						
hydroxylamine deriva	Neunhoeffer O., Gottschlich R.; "Acylating activity of O-acylated hydroxylamine derivatives"; Justus Liebigs Ann. Chem.; 736; 100-109; 1970; in German with English abstract *** Pertwee et al; Br. J. Pharmacol.; 105; 980 1992 Smith P.B. et al; "The pharmacological activity of anandamide, a putative endogenous cannabinoid," journal of pharmacology and experimental therapeutics; vol. 270(1):219-227; 1994 (abstract only, attached to Twitchell abstract) Twitchell, W. et al; "Cannabinoids inhibit N- and P/Q type calcium channels in cultured rat hippocampal neurons"; Journal of Neurophysiology; 78(1); 43-50; 1997 (database CAPLUS on STN (Columbus, OH, USA) DN 127:199945 (abstract only)					
*** Pertwee et al; Br.						
endogenous cannabi therapeutics; vol. 270						
in cultured rat hippoc 50; 1997 (database 0						
						
Examiner	Date Considered					
EXAMINER: Initial if citation considered, whe citation if not in conformance and not considered.	red. Include copy of this f	orm with next comn	PEP §609; Draw line through nunication to the applicant.			

G:\AYR saved docs\Filing Docs\Uconap\uconap141us\uconap141us 5-04 ids.doc